• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全身化疗减积联合局部治疗视网膜母细胞瘤的临床结局及消退模式:一项前瞻性研究。

Clinical outcome and regression patterns of retinoblastoma treated with systemic chemoreduction and focal therapy: A prospective study.

作者信息

Chawla Bhavna, Jain Amit, Seth Rachna, Azad Rajvardhan, Mohan V K, Pushker Neelam, Ghose Supriyo

机构信息

Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

Department of Pediatrics, Pediatric Oncology Division, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Indian J Ophthalmol. 2016 Jul;64(7):524-9. doi: 10.4103/0301-4738.190143.

DOI:10.4103/0301-4738.190143
PMID:27609166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5026079/
Abstract

PURPOSE

To prospectively study the clinical outcome and regression patterns of early retinoblastoma (Groups A and B) after systemic chemotherapy and focal consolidation in Indian children.

MATERIALS AND METHODS

Group A eyes were treated with focal therapy (transpupillary thermotherapy/cryotherapy) and Group B with systemic chemoreduction and focal therapy. Outcome measures were efficacy and safety of treatment, risk factors for treatment failure, regression patterns, and factors predictive of regression patterns.

RESULTS

Of 119 eyes (216 tumors), 14 (11.8%) were Group A and 105 (88.2%) were Group B eyes. The mean follow-up was 22.6 months. Tumor control was achieved in 111/119 eyes (93.3% overall, 100% Group A, 92.4% Group B). Eight Group B eyes (6.7%) had treatment failure. No serious systemic side-effects were noted. Risk factors for failure included larger tumors (P = 0.001) and proximity to posterior pole (P = 0.014). Regression patterns were Type 4 (50.2%), Type 3 (31.7%), Type 1 (11.1%), and Type 2 (7%). Factors predictive of Type 4 regression were smaller tumors, anterior location, younger age; Type 3 regression was associated with larger tumors, macular location, and older age.

CONCLUSIONS

Systemic chemoreduction and focal therapy provided effective tumor control in Indian children. Factors predictive of regression patterns included age, tumor size and its location, and the modality of treatment.

摘要

目的

前瞻性研究印度儿童早期视网膜母细胞瘤(A组和B组)在全身化疗和局部巩固治疗后的临床结局及消退模式。

材料与方法

A组眼睛采用局部治疗(经瞳孔温热疗法/冷冻疗法),B组采用全身化疗减瘤和局部治疗。结局指标包括治疗的有效性和安全性、治疗失败的危险因素、消退模式以及预测消退模式的因素。

结果

119只眼睛(216个肿瘤)中,14只(11.8%)为A组眼睛,105只(88.2%)为B组眼睛。平均随访时间为22.6个月。111/119只眼睛(总体93.3%,A组100%,B组92.4%)实现了肿瘤控制。8只B组眼睛(6.7%)治疗失败。未观察到严重的全身副作用。失败的危险因素包括较大的肿瘤(P = 0.001)和靠近后极(P = 0.014)。消退模式为4型(50.2%)、3型(31.7%)、1型(11.1%)和2型(7%)。预测4型消退的因素是较小的肿瘤、前部位置、较年轻的年龄;3型消退与较大的肿瘤、黄斑位置和较年长的年龄相关。

结论

全身化疗减瘤和局部治疗为印度儿童提供了有效的肿瘤控制。预测消退模式的因素包括年龄、肿瘤大小及其位置以及治疗方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/57a1f80cc042/IJO-64-524-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/e357e8e4c15c/IJO-64-524-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/cf2ef4c231bb/IJO-64-524-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/57a1f80cc042/IJO-64-524-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/e357e8e4c15c/IJO-64-524-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/cf2ef4c231bb/IJO-64-524-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4904/5026079/57a1f80cc042/IJO-64-524-g004.jpg

相似文献

1
Clinical outcome and regression patterns of retinoblastoma treated with systemic chemoreduction and focal therapy: A prospective study.全身化疗减积联合局部治疗视网膜母细胞瘤的临床结局及消退模式:一项前瞻性研究。
Indian J Ophthalmol. 2016 Jul;64(7):524-9. doi: 10.4103/0301-4738.190143.
2
Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.采用化学减容法治疗的黄斑区视网膜母细胞瘤:68例肿瘤接受或未接受辅助热疗的肿瘤控制情况分析
Arch Ophthalmol. 2005 Jun;123(6):765-73. doi: 10.1001/archopht.123.6.765.
3
Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.视网膜母细胞瘤的化学减灭术联合局部治疗:预测需行外照射放疗或眼球摘除术治疗的因素
Am J Ophthalmol. 2002 May;133(5):657-64. doi: 10.1016/s0002-9394(02)01348-x.
4
[Retinoblastoma regression patterns and results following chemo reduction and adjuvant therapy].[化疗减瘤及辅助治疗后视网膜母细胞瘤的消退模式及结果]
Zhonghua Yan Ke Za Zhi. 2012 Jul;48(7):625-30.
5
Regression patterns in treated retinoblastoma with chemotherapy plus focal adjuvant therapy.化疗联合局部辅助治疗后视网膜母细胞瘤的消退模式。
Pediatr Blood Cancer. 2013 Apr;60(4):599-604. doi: 10.1002/pbc.24333. Epub 2012 Oct 3.
6
Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.视网膜母细胞瘤的化学减灭法:457例肿瘤的肿瘤控制及复发风险分析
Trans Am Ophthalmol Soc. 2004;102:35-44; discussion 44-5.
7
Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.视网膜母细胞瘤中化学减灭术失败的原因及导致最终采用外照射放疗和眼球摘除术治疗的相关因素分析。
Ophthalmology. 2004 Oct;111(10):1917-24. doi: 10.1016/j.ophtha.2004.04.016.
8
Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors.557例肿瘤经化疗减积及辅助治疗后的视网膜母细胞瘤消退模式
Arch Ophthalmol. 2009 Mar;127(3):282-90. doi: 10.1001/archophthalmol.2008.626.
9
Thermotherapy for retinoblastoma.视网膜母细胞瘤的热疗法
Arch Ophthalmol. 1999 Jul;117(7):885-93. doi: 10.1001/archopht.117.7.885.
10
Clinical efficacy and prognostic factors of chemoreduction combined with topical treatment for advanced intraocular retinoblastoma.化疗减积联合局部治疗晚期眼内视网膜母细胞瘤的临床疗效及预后因素
Asian Pac J Cancer Prev. 2014;15(18):7805-9. doi: 10.7314/apjcp.2014.15.18.7805.

引用本文的文献

1
RB-Care: An Artificial Intelligence System for Automatic Quantitative Assessment and Surveillance of Retinoblastoma.RB-Care:一种用于视网膜母细胞瘤自动定量评估和监测的人工智能系统。
Transl Vis Sci Technol. 2025 Aug 1;14(8):15. doi: 10.1167/tvst.14.8.15.
2
Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies.视网膜母细胞瘤:关于遗传起源、分类、从传统治疗到下一代治疗策略的最新进展
Heliyon. 2024 Jun 11;10(12):e32844. doi: 10.1016/j.heliyon.2024.e32844. eCollection 2024 Jun 30.
3
Conservative treatment using laser diode and systemic chemotherapy for early-stage bilateral retinoblastoma: A 14-year prospective cohort study.

本文引用的文献

1
Efficacy of vincristine and carboplatin as chemo-reduction for advanced bilateral retinoblastoma, the Saudi experience.长春新碱与卡铂用于晚期双侧视网膜母细胞瘤化疗减瘤的疗效:沙特经验
Saudi J Ophthalmol. 2013 Jul;27(3):193-6. doi: 10.1016/j.sjopt.2013.07.009. Epub 2013 Jul 19.
2
Regression patterns in treated retinoblastoma with chemotherapy plus focal adjuvant therapy.化疗联合局部辅助治疗后视网膜母细胞瘤的消退模式。
Pediatr Blood Cancer. 2013 Apr;60(4):599-604. doi: 10.1002/pbc.24333. Epub 2012 Oct 3.
3
[Retinoblastoma regression patterns and results following chemo reduction and adjuvant therapy].
采用激光二极管和全身化疗对早期双侧视网膜母细胞瘤进行保守治疗:一项为期14年的前瞻性队列研究。
Cancer Rep (Hoboken). 2024 Jan;7(1):e1919. doi: 10.1002/cnr2.1919. Epub 2023 Oct 17.
4
Primary Macular Retinoblastoma: Clinical Presentation and Treatment Outcomes.原发性黄斑视网膜母细胞瘤:临床表现与治疗结果
J Vitreoretin Dis. 2022 Aug 4;6(5):367-373. doi: 10.1177/24741264221107757. eCollection 2022 Sep-Oct.
5
Palladium-103 plaque brachytherapy for retinoblastoma: Long term follow up.钯-103敷贴近距离放射疗法治疗视网膜母细胞瘤:长期随访
Am J Ophthalmol Case Rep. 2022 Jun 23;27:101636. doi: 10.1016/j.ajoc.2022.101636. eCollection 2022 Sep.
6
Retinoblastoma and vision.视网膜母细胞瘤与视力。
Eye (Lond). 2023 Apr;37(5):797-808. doi: 10.1038/s41433-021-01845-y. Epub 2022 Jan 5.
7
Intra-Arterial Chemotherapy: New Hope for Adult Retinoblastoma Treatment-A Case Report and Brief Review.动脉内化疗:成人视网膜母细胞瘤治疗的新希望——一例报告及简要综述
Case Rep Ophthalmol Med. 2021 Jul 9;2021:6639900. doi: 10.1155/2021/6639900. eCollection 2021.
8
Phase-based OCT angiography in diagnostic imaging of pediatric retinoblastoma patients: abnormal blood vessels in post-treatment regression patterns.基于相位的光学相干断层扫描血管造影在儿童视网膜母细胞瘤患者诊断成像中的应用:治疗后消退模式中的异常血管
Biomed Opt Express. 2019 Apr 3;10(5):2213-2226. doi: 10.1364/BOE.10.002213. eCollection 2019 May 1.
9
Recent advances and challenges in the management of retinoblastoma.视网膜母细胞瘤治疗的最新进展与挑战
Indian J Ophthalmol. 2017 Feb;65(2):133-139. doi: 10.4103/ijo.IJO_883_16.
[化疗减瘤及辅助治疗后视网膜母细胞瘤的消退模式及结果]
Zhonghua Yan Ke Za Zhi. 2012 Jul;48(7):625-30.
4
Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned?静脉内和动脉内化疗治疗视网膜母细胞瘤:我们学到了什么?
Curr Opin Ophthalmol. 2012 May;23(3):202-9. doi: 10.1097/ICU.0b013e3283524130.
5
Frontiers in the management of retinoblastoma.视网膜母细胞瘤管理前沿
Am J Ophthalmol. 2009 Aug;148(2):192-8. doi: 10.1016/j.ajo.2009.04.004. Epub 2009 May 24.
6
Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors.557例肿瘤经化疗减积及辅助治疗后的视网膜母细胞瘤消退模式
Arch Ophthalmol. 2009 Mar;127(3):282-90. doi: 10.1001/archophthalmol.2008.626.
7
Retinoblastoma: review of current management.视网膜母细胞瘤:当前治疗方法综述
Oncologist. 2007 Oct;12(10):1237-46. doi: 10.1634/theoncologist.12-10-1237.
8
Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.黄斑区视网膜母细胞瘤:化疗联合重复黄斑中心凹激光消融治疗后眼部肿瘤控制、局部并发症及视力预后评估
Ophthalmology. 2007 Jan;114(1):162-9. doi: 10.1016/j.ophtha.2006.06.042. Epub 2006 Oct 27.
9
The International Classification of Retinoblastoma predicts chemoreduction success.视网膜母细胞瘤国际分类法可预测化疗减瘤的成功率。
Ophthalmology. 2006 Dec;113(12):2276-80. doi: 10.1016/j.ophtha.2006.06.018. Epub 2006 Sep 25.
10
Intraocular retinoblastoma: the case for a new group classification.眼内视网膜母细胞瘤:一种新的分组分类方法
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii. doi: 10.1016/j.ohc.2004.11.003.